Cargando…

Prophylactic interferon-γ and interleukin-17 facilitate parasite clearance in experimental visceral leishmaniasis

BACKGROUND AND OBJECTIVE: The synergy of interleukin (IL)-17 along with other pro-inflammatory cytokines is well known in various autoimmune and infectious diseases. A longitudinal study in the Sudanese population showed an association of IL-17 with the protection of kala-azar outbreak. The protecti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kumar, Prabin, Misra, Pragya, Yadav, Narendra Kumar, Joshi, Sumit, Sahasrabuddhe, Amogh A., Dube, Anuradha, Rishi, Narayan, Mitra, Dipendra Kumar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6542311/ https://www.ncbi.nlm.nih.gov/pubmed/31161090 http://dx.doi.org/10.4103/tp.TP_32_18

Ejemplares similares

A Chimera of Th1 Stimulatory Proteins of Leishmania donovani Offers Moderate Immunotherapeutic Efficacy with a Th1-Inclined Immune Response against Visceral Leishmaniasis
por: Ratnapriya, Sneha, et al.
Publicado: (2021)

Visceral Leishmaniasis: Advancements in Vaccine Development via Classical and Molecular Approaches
por: Joshi, Sumit, et al.
Publicado: (2014)

Characterization of Glycolytic Enzymes - rAldolase and rEnolase of Leishmania donovani, Identified as Th1 Stimulatory Proteins, for Their Immunogenicity and Immunoprophylactic Efficacies against Experimental Visceral Leishmaniasis
por: Gupta, Reema, et al.
Publicado: (2014)

Immunogenicity and Protective Efficacy of T-Cell Epitopes Derived From Potential Th1 Stimulatory Proteins of Leishmania (Leishmania) donovani
por: Joshi, Sumit, et al.
Publicado: (2019)

Over-Expression of Cysteine Leucine Rich Protein Is Related to SAG Resistance in Clinical Isolates of Leishmania donovani
por: Das, Sanchita, et al.
Publicado: (2015)

Nucleosomal Histone Proteins of L. donovani: A Combination of Recombinant H2A, H2B, H3 and H4 Proteins Were Highly Immunogenic and Offered Optimum Prophylactic Efficacy against Leishmania Challenge in Hamsters
por: Baharia, Rajendra K., et al.
Publicado: (2014)

Correction: Nucleosomal Histone Proteins of L. donovani: A Combination of Recombinant H2A, H2B, H3 and H4 Proteins Were Highly Immunogenic and Offered Optimum Prophylactic Efficacy against Leishmania Challenge in Hamsters
por: Baharia, Rajendra K., et al.
Publicado: (2021)

Cloning, Expression and Purification of L. Donovani Specific Antigen for Serodiagnosis of Visceral Leishmaniasis
por: Kumar, Dinesh, et al.
Publicado: (2013)

Immunobiology of visceral leishmaniasis
por: Kumar, Rajiv, et al.
Publicado: (2012)

Supplementation of host response by targeting nitric oxide to the macrophage cytosol is efficacious in the hamster model of visceral leishmaniasis and adds to efficacy of amphotericin B
por: Pandya, Sanketkumar, et al.
Publicado: (2016)

Th1 Stimulatory Proteins of Leishmania donovani: Comparative Cellular and Protective Responses of rTriose Phosphate Isomerase, rProtein Disulfide Isomerase and rElongation Factor-2 in Combination with rHSP70 against Visceral Leishmaniasis
por: Jaiswal, Anil Kumar, et al.
Publicado: (2014)

Leishmania donovani Triose Phosphate Isomerase: A Potential Vaccine Target against Visceral Leishmaniasis
por: Kushawaha, Pramod K., et al.
Publicado: (2012)

Evaluation of Leishmania donovani Protein Disulfide Isomerase as a Potential Immunogenic Protein/Vaccine Candidate against Visceral Leishmaniasis
por: Kushawaha, Pramod Kumar, et al.
Publicado: (2012)

Regulatory T Cells Suppress T Cell Activation at the Pathologic Site of Human Visceral Leishmaniasis
por: Rai, Ambak K., et al.
Publicado: (2012)

Visceral Leishmaniasis Clinical Management in Endemic Districts of India, Nepal, and Bangladesh
por: Banjara, Megha Raj, et al.
Publicado: (2012)

Post-kala-azar Dermal Leishmaniasis Developing in Miltefosine-Treated Visceral Leishmaniasis
por: Koley, Sankha, et al.
Publicado: (2013)

Chronic Kappa opioid receptor activation modulates NR2B: Implication in treatment resistant depression
por: Dogra, Shalini, et al.
Publicado: (2016)

Immune Regulation during Chronic Visceral Leishmaniasis
por: Faleiro, Rebecca J., et al.
Publicado: (2014)

Visceral leishmaniasis
por: Sundar, Shyam
Publicado: (2015)

Dropout Analysis of a National Social Health Insurance Program at Pokhara Metropolitan City, Kaski, Nepal
por: Sharma, Prabin, et al.
Publicado: (2021)

Recombinant NAD-dependent SIR-2 Protein of Leishmania donovani: Immunobiochemical Characterization as a Potential Vaccine against Visceral Leishmaniasis
por: Baharia, Rajendra K, et al.
Publicado: (2015)

Pharmacotherapeutic Options for Visceral Leishmaniasis—Current Scenario
por: Pandey, Krishna, et al.
Publicado: (2009)

Visceral leishmaniasis outbreak in Kenya—a setback to the elimination efforts
por: Mewara, Abhishek, et al.
Publicado: (2022)

Linoleic Acid—A Feasible Preventive Approach for Visceral Leishmaniasis
por: Saini, Sheetal, et al.
Publicado: (2021)

Correction: Recombinant NAD-dependent SIR-2 Protein of Leishmania donovani: Immunobiochemical Characterization as a Potential Vaccine against Visceral Leishmaniasis
por: Baharia, Rajendra K, et al.
Publicado: (2015)

Miltefosine Rescue Treatment for Visceral Leishmaniasis Relapse Patient
por: Bastola, Anup, et al.
Publicado: (2019)

Relationship between treatment regimens for visceral leishmaniasis and development of post-kala-azar dermal leishmaniasis and visceral leishmaniasis relapse: A cohort study from Bangladesh
por: Mondal, Dinesh, et al.
Publicado: (2019)

Comparative Analysis of Cellular Immune Responses in Treated Leishmania Patients and Hamsters against Recombinant Th1 Stimulatory Proteins of Leishmania donovani
por: Joshi, Sumit, et al.
Publicado: (2016)

Wnt5A Signaling Blocks Progression of Experimental Visceral Leishmaniasis
por: Maity, Shreyasi, et al.
Publicado: (2022)

Congenital Visceral Leishmaniasis
por: Boehme, Catharina C., et al.
Publicado: (2006)

Immunity to Visceral Leishmaniasis
por: Ali, Nahid, et al.
Publicado: (2012)

Treatment of Visceral Leishmaniasis
por: Moore, E M, et al.
Publicado: (2010)

Epidemiology of visceral leishmaniasis
por: Ready, Paul D
Publicado: (2014)

Quality of life perceptions amongst patients co-infected with Visceral Leishmaniasis and HIV: A qualitative study from Bihar, India
por: Nair, Mohit, et al.
Publicado: (2020)

Type I Interferons Suppress Anti-parasitic Immunity and Can Be Targeted to Improve Treatment of Visceral Leishmaniasis
por: Kumar, Rajiv, et al.
Publicado: (2020)

Visceral Leishmaniasis Elimination Programme in India, Bangladesh, and Nepal: Reshaping the Case Finding/Case Management Strategy
por: Mondal, Dinesh, et al.
Publicado: (2009)

Microalbuminuria and Glomerular Filtration Rate in Paediatric Visceral Leishmaniasis
por: Verma, Neena, et al.
Publicado: (2013)

Gender disparity in cases enrolled in clinical trials of visceral leishmaniasis: A systematic review and meta-analysis
por: Dahal, Prabin, et al.
Publicado: (2021)

Membrane‐acting biomimetic peptoids against visceral leishmaniasis
por: Kumar, Vivek, et al.
Publicado: (2023)

Identification of Leishmania donovani antigen in circulating immune complexes of visceral leishmaniasis subjects for diagnosis
por: Jamal, Fauzia, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_vmeih83fdhfj9u84aj5kcmnkkn